ALRN News and Press, Aileron Therapeutics Inc. From 01/12/24

2024-01-12 07:34:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! Moving stocks are investments, acquisitions, new agr...

2023-12-18 08:26:30 ET Losers: Chanson International Holding ( CHSN ) -88% . Inno Holdings ( INHD ) -85% . Maison Solutions ( MSS ) -84% issues statement regarding short attack on its securities . Aadi Bioscience ( AADI ) -56% . Sing...

2023-12-15 13:25:40 ET Gainers: Getaround ( GETR ) +116% . Battalion Oil Corp ( BATL ) +82% . La Rosa Holdings Corp. ( LRHC ) +45% . Verrica Pharmaceuticals ( VRCA ) +37% . Bruush Oral Care ( BRSH ) +36% . NCS Multistage Hold...

2023-12-15 10:00:27 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Myomo, Aileron...

2023-12-15 08:38:22 ET Losers: Aadi Bioscience AADI -54% on study data for anti-tumor drug . Inno Holdings ( INHD ) -45% . Eos Energy Enterprises EOSE -23% announces launch of proposed $40M public offering . Chavant Capital Acquisition Corp ( CLAY...

2023-11-06 12:51:18 ET Gainers: MSP Recovery ( LIFW ) +458% . Bluegreen Vacations Holding Corporation ( BVH ) +106% . Tenon Medical ( TNON ) +72% . Cano Health ( CANO ) +43% . Cheetah Net Supply Chain Service ( CTNT ) +36% . ...

2023-11-01 14:50:52 ET More on Aileron Financial information for Aileron Therapeutics For further details see: Aileron gains after all-stock deal to acquire Lung Therapeutics

Aileron Therapeutics Announces Acquisition of Lung Therapeutics PR Newswire Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibros...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q3 2023

Aileron Therapeutics ( NASDAQ: ALRN ) shed ~38% on Tuesday after the company disclosed plans to explore strategic alternatives, including a sale, and said that its Phase 1b study for chemoprotective agent ALRN-6924 failed in patients with p53-mutated breast cancer. The open-label ...